trending Market Intelligence /marketintelligence/en/news-insights/trending/q5GGmkxtHFH9MQpzNS7LcQ2 content esgSubNav
In This List

Oxford Immunotec to repurchase $100M ordinary shares

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Oxford Immunotec to repurchase $100M ordinary shares

Oxford Immunotec Global PLC said its board approved the repurchase up to $100 million of the company's ordinary shares within a five-year period.

The share repurchase program, intended to enhance shareholder value, is subject to shareholder approval at the company's annual general meeting scheduled for June 18.

The transaction will be financed using some of the proceeds from the sale of Oxford Immunotec's U.S. laboratory services business in November 2018, CEO Peter Wrighton-Smith said.

U.K.-based Oxford Immunotec is a diagnostics company focused on developing and commercializing proprietary tests for underserved immune-regulated conditions.